ArticleTranslational cancer research2025
Unveiling prognostic factors and predictive modeling in lung adenocarcinoma with neuroendocrine differentiation.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Some lung cancer patients are pathologically confirmed to have lung adenocarcinoma with neuroendocrine differentiation (LUAD-ND). However, research on this subtype remains limited. This study aimed to systematically investigate the metastatic patterns and prognosis-related factors of LUAD-ND, and construct neural network-based prediction models for survival outcomes. Methods: By analyzing the Surveillance, Epidemiology, and End Results (SEER) database, we employed the Cox proportional hazards model to investigate prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in patients with LUAD-ND. We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) and detailed the median survival time and specific time survival probabilities for different features in the LUAD-ND population. Finally, using a neural network algorithm, we developed a predictive model for forecasting LUAD-ND's OS and CSS, evaluating its performance using the area under the receiver operating characteristic curve (AUC). Results: Most patients with LUAD-ND were diagnosed at an advanced stage. The OS time of patients with LUAD-ND was 12 (95% CI: 10-14) months, and the CSS time was 14 (95% CI: 12-16) months. The most common distant metastatic sites were bone, followed by liver, brain, and lung. Surgery (HR =0.51; 95% CI: 0.31-0.82; P=0.006) and chemotherapy (HR =0.33; 95% CI: 0.21-0.50; P<0.001) were associated with improved OS. Similarly, surgery (HR =0.49; 95% CI: 0.28-0.84; P=0.01) and chemotherapy (HR =0.31; 95% CI: 0.19-0.49; P<0.001) were linked to better CSS. The neural network-based tool can effectively predict the prognosis of LUAD-ND, achieving an AUC of 0.852-0.864 for 6-month OS and 0.835-0.883 for 6-month CSS. Conclusions: Patients with LUAD-ND face a dismal prognosis, yet chemotherapy and surgical interventions can ameliorate their outcomes. The neural network tool developed in this study yields precise prognostic estimations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.